Bausch Health Companies Inc. is a diversified healthcare firm specializing in specialty pharmaceuticals and medical devices, primarily in gastroenterology and hepatology. The company boasts strong gross (72.9%) and EBITDA margins (35.9%), indicating efficient operations; however, its net margin (9.0%) and return on assets (1.0%) raise concerns about profitability and asset utilization. Additionally, while the current (1.44) and quick ratios (1.08) suggest adequate liquidity, the stock's recent decline (-2.64%) may reflect market skepticism despite solid margins. Overall, BHC's high margins contrast with its low valuation, warranting cautious observation.
Loading financial metrics...
Company posted a loss of $-1.1B over the last year, representing 10.1% of revenue.
Debt of $20.8B is 11.4x the company's cash position of $1.8B.
Revenue growing at 10.1% YoY, outpacing typical market growth rates.
Operating margin expanded by 5.3pp, demonstrating strong operational leverage.
Both gross margin (+1.7pp) and operating margin (+5.3pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 72.4% indicates strong pricing power and competitive moat.
Operating cash flow grew 19.5% YoY, demonstrating improving cash conversion.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q2 (June 30, 2026)